Clinical Trials
19 trialsNCT03761108 2026-04-20
LINKER-MM1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04404660 2026-04-08
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
Phase 1/2 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT02598661 2026-01-05
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation
Phase 2/3 Active not recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT03981796 2025-09-03
RUBY
Tesaro, Inc.
Phase 3 Active not recruiting
NCT03581786 2025-09-02
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT03575351 2025-08-03
TRANSFORM
Celgene
Phase 3 Completed
NCT02074839 2025-06-08
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
Phase 1 Recruiting
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT02614066 2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2 Completed
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT02000427 2024-05-28
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2 Completed
NCT02445248 2024-04-18
JULIET
Novartis
Phase 2 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed